Drs Alexey Danilov and Anthony Mato highlight their preferences for diagnostic and prognostic testing when evaluating patients with chronic lymphocytic leukemia.
Back
Updates in CLL: Optimizing Testing Rates
Preferences for conducting molecular testing in patients with chronic lymphocytic leukemia to guide treatment decisions based on evolving novel combination regimens used as frontline therapy.
Updates in CLL: Optimizing Testing Rates
Episodes
All
All
The types of prognostic assays used to help determine candidacy for chemoimmunotherapy as frontline treatment for chronic lymphocytic leukemia.
Recommendations for conducting imaging scans and biopsies to help guide the treatment of newly diagnosed chronic lymphocytic leukemia.
Drs Alexey Danilov and Anthony Mato recommend when hematologists and oncologists should consider repeat molecular testing for patients with chronic lymphocytic leukemia.
Drs Alexey Danilov and Anthony Mato review treatment options available for newly diagnosed chronic lymphocytic leukemia and describe decisions for monotherapy vs combination therapy.
Considerations for using novel fixed-duration regimens and triplet therapy to treat patients with chronic lymphocytic leukemia.
Circumstances for which MRD testing may be considered for patients with chronic lymphocytic leukemia.
Drs Alexey Danilov and Anthony Mato respond to a variety of questions pertaining to the assessment and treatment of patients with chronic lymphocytic leukemia.
Advertisement
Advertisement
Trending on OncLive
1
Five Under 5: Top Oncology Videos for the Week of 8/31/26
2
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
3
B7-H4–Targeted ADCs Signal a New Frontier for Platinum-Resistant Ovarian and Endometrial Cancer
4
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
5